M Mitrovic1,2, I Elezovic1,2, N Suvajdzic-Vukovic1,2. 1. Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia. 2. Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR). CASE SUMMARY: We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 109 /L, over a period of 12 months. WHAT IS NEW AND CONCLUSION: The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety.
WHAT IS KNOWN AND OBJECTIVE: Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR). CASE SUMMARY: We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 109 /L, over a period of 12 months. WHAT IS NEW AND CONCLUSION: The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety.
Authors: H C Cai; S J Wang; L Fu; X M Wang; M Hou; P Qin; F P Chen; X H Zhang; H Huang; J S He; R H Wu; J Y Ma; R C Yang; X F Liu; Y Tian; A J Liu; J S Wu; W W Zhu; Y H Zhou; W B Liu; Y Hu; W J He; Y Li; D Pan; Y Q Zhao Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2017-05-14